Fig. 3: Landmark progression-free and overall survival analyses for patients with LBCL (N = 157). | Leukemia

Fig. 3: Landmark progression-free and overall survival analyses for patients with LBCL (N = 157).

From: Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Fig. 3

Progression-free survival per IRC assessment (A) and overall survival (B) analysis by minimal residual disease assessment up to cycle 3 day 1 for patients with LBCL (N = 157). Landmark analyses excluded patients who had an event or were censored before cycle 3 day 1. C cycle, D day, IRC Independent Review Committee, LBCL large B-cell lymphoma, MRD minimal residual disease.

Back to article page